Clearpoint Neuro (CLPT) investor relations material

Executive summary

• Achieved record Q2 2025 revenue of $9.2 million, up 17% year-over-year, driven by growth in neurosurgery navigation, biologics, and therapy products, and supported by over 60 biopharma partners.

• Net loss widened to $5.8 million for Q2 2025, reflecting higher R&D, G&A, and sales expenses.

• Cash and equivalents reached $41.5 million as of June 30, 2025, up from $20.1 million at year-end 2024, following $32 million in new funding from note and equity offerings.

• Multiple growth initiatives underway, including expansion into new markets, products, and partnerships, and scaling global reach.

• Achieved strategic milestones such as first US-based commercial neuro cell and gene therapy cases and expanded preclinical research capacity.

Financial highlights

• Q2 2025 revenue was $9.2 million, up from $7.9 million in Q2 2024; product revenue grew 21% to $6.0 million, service revenue rose 10% to $3.2 million.

• Gross margin was 60% in Q2 2025, down from 63% in Q2 2024, mainly due to higher inventory reserves.

• Operating expenses increased 16% year-over-year to $11.2 million, with R&D up 23%, sales and marketing up 5%, and G&A up 23%.

• Net loss per share was $(0.21) in Q2 2025, compared to $(0.16) in Q2 2024.

• Cash used in operating activities for the first half of 2025 was $8.7 million.

Outlook and guidance

• Reaffirmed full-year 2025 revenue guidance of $36.0 million to $41.0 million.

• Expecting 15–20 new site activations in 2025, with 11–16 in the second half, and planning to accelerate US site activations in H2 2025.

• Management believes current cash balances are sufficient to support operations for at least the next twelve months.

• Anticipate additional cell and gene therapy platforms to be approved in the next 2–3 years.

• Growth opportunities depend on partners' clinical and regulatory progress and macroeconomic trends.